MedTrace Logo

Idiopathic Pulmonary Fibrosis Cohort of TCM

NCT07162870 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2025-09-09

No results posted yet for this study

Summary

This study, based on past registration records, evaluates the clinical efficacy of traditional Chinese medicine in treating IPF in the real world, identifies advantageous populations and clinical targets, and provides references for precision traditional Chinese medicine treatment.

Conditions

  • Idiopathic Pulmonary Fibrosis (IPF)

Interventions

DRUG

Traditional Chinese medicine (TCM)

Regulated use of Chinese medicine treatment protocols is included as an exposure factor. Exposure is defined as taking the medication continuously for more than 3 months per year, or intermittently for more than 6 months per year. According to the standardised use of TCM protocols, the group is divided into an exposed group (TCM cohort) and an unexposed group (non-TCM cohort).

DRUG

Non-traditional Chinese medicine (non-TCM)

All intervention measures that do not meet the criteria for TCM exposure are regarded as non-TCM exposure.

Sponsors & Collaborators

  • The First Affiliated Hospital of Henan University of Traditional Chinese Medicine

    collaborator OTHER

  • China-Japan Friendship Hospital

    collaborator OTHER

  • The First Affiliated Hospital of Zhengzhou University

    collaborator OTHER

  • Shanghai Pulmonary Hospital, Shanghai, China

    collaborator OTHER

  • Henan University of Traditional Chinese Medicine

    lead OTHER

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-05
Primary Completion
2028-10-30
Completion
2028-11-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07162870 on ClinicalTrials.gov